Research & Development



第一六一章 劉徹的疑惑   劉二的儺舞表演的極好,哪怕是沒了半截胳膊,他的舞姿一樣充滿了神秘感,當帶著山魈面具的劉二嘴里咬著刀子搖頭擺尾的時候,雲氏僕婦在劉婆的帶領下,齊齊的向主人夫婦行禮,承認從今往後,宋喬將是家里的女主人。久久精品视频在线看15   雲瑯雖然不能輕易殺掉,卻能通過律法,時不時地罰罰銅,降降罪讓雲氏保持一定的規模,卻不至于坐大。色哥哥-最新成人激情网   想到公孫弘登上相位,董仲舒未免有些失落……   不管劉徹跟阿嬌現在是如何的如膠似漆,在皇權不受威脅這個前提下,劉徹依舊是清醒的。一本道久久久999   “試藥!”雲瑯呲著一嘴的白牙笑著對阿嬌道。

Our discovery and development platforms for drug and cell-based therapies allow us to both create and retain significant value within our therapeutic franchise areas of cancer and inflammatory diseases. Scientists and physicians at Celgene are the driving force behind our success, enabling target-to-therapeutic platforms that integrate both small-molecule and cell-based therapies.

Connect? Registries

The Connect??Registries are observational, hematologic patient registry studies in Multiple Myeloma (Connect?MM), Chronic Lymphocytic Leukemia (Connect?CLL) and Myelodysplastic Syndromes/Acute Myeloid Leukemia (Connect?MDS/AML) and are sponsored by Celgene Corporation. These studies are designed to observe the routine care of patients through the course of their disease. Unlike clinical trials, registries do not require or provide any specific medications or healthcare services, but leave those decisions to the treating doctors and their patients.
Connect? Registries logo